Wainua Trial Setback Sends Ionis Plunging and Drags Down AstraZeneca
AstraZeneca and Ionis’s Wainua missed its primary endpoint in the Phase 3 ATTR-CM trial, while competitors Alnylam and BridgeBio surged.
/ 7 items
#BBIO↓
FDA Fast-Tracks First-Ever Treatment for Rare Muscle Disease LGMD2I/R9
BridgeBio’s BBP-418 receives FDA Priority Review with a November 27, 2026 PDUFA date. If approved, it would be the first therapy for LGMD2I/R9 and any form of limb-girdle muscular dystrophy.
Pfizer Delays Generic Vyndamax Until 2031 – Great News for BridgeBio’s Attruby
Pfizer extends Vyndamax patent to 2031, delaying generics and giving BridgeBio more time to grow its rival heart drug without pressure.
BridgeBio Stock Gets Double Upgrade: Analysts See $93–$94 Target Ahead
JPMorgan & William Blair raise BridgeBio price targets to $93–$94 on strong Attruby launch and achondroplasia data.
Ascendis Pharma Scores FDA Approval for Yuviwel – Weekly Injection to Boost Growth in Achondroplasia
FDA approves Ascendis Pharma's Yuviwel, the first once-weekly injection to boost growth in children 2+ with achondroplasia. Launch expected Q2 2026.
BridgeBio's Breakthrough: Oral Drug Succeeds in Dwarfism Study
BridgeBio's oral infigratinib outperforms BioMarin's injectable therapy in boosting growth for kids with achondroplasia, marking a major win in treating the genetic cause of dwarfism.